| 1016 |
Early Versus Delayed Antihypertensive Treatment After Acute Ischemic Stroke by Hypertension History (CATIS-2 Trial)
|
2025-02-27 |
131 |
| 1015 |
Endovascular Treatment of Stroke Due to Medium-Vessel Occlusion (ESCAPE-MeVO Trial)
|
2025-02-27 |
142 |
| 1014 |
Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels
|
2025-02-27 |
124 |
| 1013 |
Endovascular therapy for acute vertebrobasilar occlusion (VERITAS): a systematic review and individual patient data meta-analysis
|
2025-01-31 |
174 |
| 1012 |
Surgical Management of Intracerebral Hemorrhage: New Light on the Horizon?
|
2025-01-31 |
218 |
| 1011 |
Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
|
2025-01-31 |
203 |
| 1010 |
Large-Core Ischemic Stroke Endovascular Treatment: A Science Advisory From the American Heart Association
|
2024-12-31 |
316 |
| 1009 |
Effect of IV Thrombolysis With Alteplase in Patients With Vessel Occlusion in the WAKE-UP Trial
|
2024-12-31 |
260 |
| 1008 |
Liberal or Restrictive Transfusion Strategy in Aneurysmal Subarachnoid Hemorrhage
|
2024-12-31 |
238 |
| 1007 |
Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation
|
2024-12-03 |
386 |
| 1006 |
Tenecteplase vs Alteplase in Acute Ischemic Stroke Within 4.5 Hours
|
2024-12-03 |
395 |
| 1005 |
Tenecteplase versus alteplase for acute stroke within 4·5 h of onset (ATTEST-2): a randomised, parallel group, open-label trial
|
2024-12-03 |
432 |
| 1004 |
White Matter Hyperintensities and Cognitive Functions in People With the R544C Variant of the NOTCH3 Gene Without Stroke or Dementia
|
2024-11-01 |
473 |
| 1003 |
Duration of Benefit and Risk of Dual Antiplatelet Therapy up to 72 Hours After Mild Ischemic Stroke and Transient Ischemic Attack
|
2024-11-01 |
461 |
| 1002 |
Adjunctive Intravenous Argatroban or Eptifibatide for Ischemic Stroke
|
2024-11-01 |
384 |
HOME
LOGIN
